Can lithium salts prevent depressive episodes in the real world?

González‐Pinto, Ana; López-Peña, Purificación; Bermúdez-Ampudia, Cristina; Vieta, Eduard; Martínez‐Cengotitabengoa, Mónica

doi:10.1016/j.euroneuro.2018.09.008

Cited by 16 publications

(11 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While seemingly just a simple elemental compound, it has powerful treatment effects for both depression and bipolar disorder. Lithium is still one of few drugs that have been proven to reduce the risk of suicidality and prevention for depressive symptoms, and it may have utility in illnesses beyond affective disorders in recent years [2,3].…”

Section: Discussionmentioning

confidence: 99%

“…(2) The detection rate of or cases of switch was reported directly in study. (3) The rate of changing therapeutic plan was due to psychopathology of mania or hypomnia or very irritable or very compulsive. (4) The the case numbers of study patients with higher 11 score of YMRS or FMRS .…”

Section: Inclusion and Exclusion Criteriamentioning

confidence: 99%

“…As a classic mood stabilizer, lithium carbonate can be used in depressive episode for the following reasons.First,lithium carbonate has a obvious action of anti-suicide [1,2], because suicide is a emergency in psychiatric clinic,especially in adolescent bipolar disorder,which always is with trait of suicide [2].Second,lithium has anti-depressant role.Taking into account good adherence to drug treatment, in clinical practice settings, long-term lithium salts seem to have a preventive effect on depressive symptoms [3]. Third,lithium can strengthen the role of antidepressant in treatment for depression.This point views was proven in STAR*D, although more participants discontinued lithium due to adverse effects than discontinued others [4].Forth, lithium had a same anti-depressant role as lamotrigine in bipolar depression,late was called "mood stabilizer for depression" and they all are recommended for bipolar depression in treatment guideline of bipolar disorder [5,6].So many studies results are the reasons of lithium in treatment for depressive episode.…”

Section: Introductionmentioning

confidence: 99%

“…Some improve signi cantly, while others, especially those with concomitant manic symptoms, have had previous episodes of treatment-emergent mania or are rapid cyclers, exhibit manic switches or cycle acceleration [12]. The one of methods in avoidance switch was use of mood stabilizer,especially lithium carbonate [3,10,11,12].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

How About Effect of Lithium Carbonate on Preventive Switch Induced by Antidepressants in Patients With Depressive Episode? Chinese Data Analysis

Lv¹,

Tao

Sun

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Although mania or hypomania was defined as indispensable for bipolar disorder, depressive episodes are more common and impairing, with proven response to treatments.So the prevention switch was a important affair in clinical psychiatryMethods: We searched CBM, CNKI, WANFANG and CSSCI in Chinese to find literature from July 1 2000 to July 31 2020 related to the study in model of “comparison of switch rate between combination treatment of lithium and antidepressant and monotherapy of antidepressant in patients with depressive episode”, among which results such as comments, letters, reviews and case reports were excluded. The rate of switch between groups was synthesized and discussed. Result: A total of 695 subjects were included in 9 studies. Random effect model is used to account for the data by Revman 5.2. The results showed that the switch rate of lithium carbonate was 8.28%(29/350),switch rate of antidepressant was 25.29%(87/344), which was very different in switch rate(OR=0.25, 95% CI: 0.16–0.39) and also indicated that lithium reduced switch rate was 67.25%(25.29%-8.28%/25.29%). In bipolar depression group, lithium reduced switch rate was 68.11%(25.84%-8.24%/25.84%). In depression group, lithium reduced switch rate was 67.34%(25.29%-8.26%/25.29%). In group of patients treated by SSRI, lithium reduced switch rate was 60.3%(29.85%-11.85%/29.85%).In group of patients treated by TCA, lithium reduced switch rate was 73.14%(22.28%-6.01%/22.28%). Conclusion: As typical mood stabilizer, lithium carbonate can reduced switch rate related to antidepressant in patients with depressive episode.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Inclusion and Exclusion Criteriamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

How About Effect of Lithium Carbonate on Preventive Switch Induced by Antidepressants in Patients With Depressive Episode? Chinese Data Analysis

Lv¹,

Tao

Sun

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…In this regard, lithium continues to be the gold standard treatment supported by extensive scienti c evidence (Carvalho et al, 2020). Both in controlled clinical trials and observational studies lithium has shown its e cacy and superiority in the prophylaxis of any type of affective episode (Berk et al, 2017a;González-Pinto et al, 2018;Kessing et al, 2017;Lähteenvuo et al, 2018;Miura et al, 2014;Severus et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Overview of Lithium´s Use: A Nationwide Survey

Mendiola

Hidalgo‐Mazzei

Vieta

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Lithium is considered the gold standard treatment for bipolar disorder (BD). Its use as a first-line treatment in BD is supported by current clinical guidelines and scientific evidence. However, over the last two decades it has been observed a downward tendency in lithium´s use in several developed countries. Based on a nationwide survey, the objective of this study is to analyze in a large sample of psychiatrists relevant issues of the use of lithium salts in BD.Methods: Data were collected through an anonymous survey sent by email among 500 psychiatrists who belong to a National Society of Psychiatry (Spanish Society of Biological Psychiatry). The survey is a self-administered questionnaire consisting of 21 items on the most key aspects of the use of lithium (indication, dosage, monitoring and information for patients).Results: 212 psychiatrists completed the survey. 70% of psychiatrists prescribe lithium to more than 50% of patients diagnosed with BD. Adverse effects are the main reason not to use lithium salts. Over 75% of the participants consider lithium salts the treatment of choice for the maintenance phase of BD, both in women and men. Most of the participants (> 50%) start lithium after the first affective episode, use conservative plasma concentrations (0.6-0.8 mmol/L) and generally prescribe it twice a day. 57% of psychiatrists who treat patients under 18 do not use lithium in this population. About 70% of the survey respondents use official protocols to inform and monitor patients who are on lithium treatment.Conclusions: From the results of the present study it can be concluded that the use of lithium in Spain is in line with the recommendations of the main international clinical guidelines and current scientific literature. The first reason not to prescribe lithium in our country is the perception of its adverse effects and not the aspects related to its practical use or its effectiveness. Considering that BD is a chronic disease that has a typical onset in adolescence, the reasons for the low rate of prescription of lithium salts in patients under 18 must be thoroughly studied.

show abstract